Anil Hingorani, MD
Vascular Surgery · Brooklyn, NYNPI 1396738100
Payments from drug & device makers
Across 37 payments — averaging $499.13 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Angiodynamics, Inc.$16K
- Convatec Inc.$850
- Silk Road Medical, Inc.$720
- W. L. Gore & Associates, Inc.$222
- Boston Scientific$211
- Bolton Medical Inc$148
- plus $304 from 5 others
What the payments were for
- Consulting fees$8505%
- Travel & lodging$6443%
- Food & beverage$9745%
- Education$3,20017%
- Other$12,80069%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Angiodynamics, Inc. | 11 | $16,013 |
| Convatec Inc. | 1 | $850 |
| Silk Road Medical, Inc. | 5 | $720 |
| W. L. Gore & Associates, Inc. | 4 | $222 |
| Boston Scientific | 10 | $211 |
| Bolton Medical Inc | 1 | $148 |
| Penumbra, Inc. | 1 | $145 |
| Abbott | 1 | $70 |
| Siemens Medical Solutions USA, Inc. | 1 | $40 |
| Medtronic | 1 | $26 |
| Advanced Oxygen Therapy Inc. | 1 | $24 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- VenaCure 1470 Pro$16,000
- InnovaMatrix AC$850
- ENROUTE Transcarotid Neuroprotection System$612
- ENROUTE Transcarotid Stent System$612
- ENHANCE Transcarotid Peripheral Access Kit$612
- ENROUTE 0.014 Guidewire$612
- RELAY THORACIC STENT-GRAFT WITH PLUS DELIVERY SYSTEM$148
- Indigo System$145
- VIABAHN Endoprosthesis with PROPATEN Bioactive Surface$105
How this compares
$18,468 in reported general payments places this provider in the 70th percentile of 405 vascular surgery providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 90 | $90,731 |
| XareltoRivaroxaban | 41 | $42,505 |
| SantylCollagenase Clostridium Hist. | 12 | $3,507 |
| Pentoxifylline | 65 | $3,258 |
| ClopidogrelClopidogrel Bisulfate | 60 | $754 |
| Cephalexin | 40 | $600 |
| Cilostazol | 30 | $511 |
| Ciprofloxacin Hcl | 54 | $455 |
| Doxycycline Hyclate | 27 | $258 |
| Clindamycin Hcl | 18 | $256 |
| Clotrimazole | 12 | $255 |
| Silver Sulfadiazine | 19 | $95 |
Paid to pharmacies, not to this prescriber.
Other vascular surgery in Brooklyn
- Robert RheeBrooklyn$406K
- Nicole IlonzoBrooklyn$94K
- Michael ShapiroBrooklyn$54K
- Gary GelbfishNew York$1.9M
- Sundaram RavikumarDobbs Ferry$1.8M
- Antonios GasparisHuntington$1.7M
- John LantisNew York$1.4M
- Sonya NoorBuffalo$1.2M
- Brian DerubertisNew York$1M
- Thomas MaldonadoNew York$1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.